The present invention relates to endolysin variants comprising an endolysin to which a peptide stretch with membrane or LPS disrupting activity is fused. Moreover, the present invention relates to nucleic acid molecules encoding said modified endolysin variant, vectors comprising said nucleic acid molecules and host cells comprising either said nucleic acid molecules or said vectors. In addition, the present invention relates to a method for producing said endolysin variant. Further, the present invention relates to said modified endolysin variant for use as a medicament, in particular for the treatment or prevention of Gram-negative bacterial infections, as diagnostic means, disinfectant or as cosmetic substance. The present invention also relates to the removal or reduction or prevention of Gram-negative bacterial contamination of foodstuff, of food processing equipment, of food processing plants, of surfaces coming into contact with foodstuff, of medical devices, of surfaces in hospitals and surgeries. Furthermore, the present invention relates to the use of said endolysin variant as a diagnostic means in medicinal, food or feed or environmental diagnostic. Finally, the present invention relates to a pharmaceutical composition comprising said modified endolysin variant.

The invention relates to, inter alia, a fusion protein comprising a protein of interest and an affinity tag which binds lysozyme. Lysozyme can be used to purify, precipitate, or support the crystallization of such a fusion protein. The invention further relates to a binding agent which specifically binds a target compound, wherein the binding agent has a CDR3 region which is derived from a single-domain antibody but which does not comprise framework regions or other elements for stabilizing the CDR3 region, and wherein the binding agent binds the target compound via the CDR3 region.

The present invention relates to chimeric endolysin Lys109 which effectively controls Staphylococcus aureus, wherein the endolysin Lys109 of the present invention has a novel amino acid sequence that has not been conventionally studied. Endolysin Lys109 of the present invention can be used as a biological regulator capable of effectively inhibiting a wide range of Staphylococcus aureus and a biofilm produced thereby. In addition, endolysin Lys109 can kill Staphylococcus aureus without regard for resistance to conventional antibiotics, and thus can be widely used for treatment of diseases caused by Staphylococcus aureus infection. Moreover, endolysin Lys109 can also be used to resolve medical problems caused by Staphylococcus aureus which has antibiotic resistance.

The subject invention pertains to lysins fused to a CeA peptide fragment, particularly at the C-terminus of the lysin. The subject invention also pertains to recombinant DNA encoding said lysins, vectors encoding said recombinant DNA, host cells comprising said vectors, and compositions comprising said lysins. The invention further pertains to a method of treating a bacterial infection, particularly a Gram-negative bacterial infection.

The present invention relates in general to the field of antimicrobial enzymes. In particular, the present invention relates to a polypeptide comprising the amino acid sequence of a globular Gram-negative endolysin and the amino acid sequence of a cell wall binding domain of i) a modular Gram-negative endolysin or ii) a bacteriophage tail/baseplate protein. The present invention relates also to corresponding nucleic acids, vectors, bacteriophages, host cells, and compositions. The present inventions also relates to the use of the polypeptide, nucleic acids, vectors, bacteriophages, host cells, and compositions in methods for treatment of the human or animal body by surgery or therapy or in diagnostic methods practiced on the human or animal body. The polypeptides, nucleic acids, vectors, bacteriophages, host cells, and compositions according to the invention may also be used as an antimicrobial in, e.g., food or feed, in cosmetics, or as disinfecting agent.

The present disclosure relates to a novel spherical agglomeration method for proteins, and protein particles made by the spherical agglomeration method. By using continuous oscillatory baffled crystallizer, the method of the present disclosure is capable of maintain the biologically activities and providing protein particles with an average particle size between 1-500 μm.

Disclosed herein are methods for improving a parameter of a protein-related process comprising providing a viscosity-reducing excipient compound selected from the group consisting of hindered amines, aromatics and anionic aromatics, functionalized amino acids, oligopeptides, short-chain organic acids, low molecular weight aliphatic polyacids, diones and sulfones, zwitterionic excipients, and crowding agents with hydrogen bonding elements, and adding a viscosity-reducing amount of the viscosity-reducing excipient compound to a carrier solution for the protein-related process, wherein the carrier solution contains a protein of interest, and carrier solutions comprising a liquid medium in which is dissolved a protein of interest, and a viscosity-reducing excipient, wherein the viscosity of the carrier solution has a lower viscosity that that of a control solution that is substantially similar to the carrier solution except for the presence of the viscosity-reducing excipient.

The present disclosure relates to methods for restoring or augmenting bactericidal activity of an antibiotic in an organ or tissue in which pulmonary surfactant is present. More specifically, the present disclosure describes that inhibition of antibiotics due to environmental factors, such as the presence of pulmonary surfactant in an organ or tissue such as the respiratory epithelium can be sidestepped or overcome and the effectiveness of the antibiotic in that milieu restored or augmented by co-administration of an antibiotic and a lysin.

Disclosed herein are methods for improving a parameter of a protein-related process comprising providing a viscosity-reducing excipient compound selected from the group consisting of hindered amines, anionic aromatics, functionalized amino acids, oligopeptides, short-chain organic acids, and low molecular weight aliphatic polyacids, and adding a viscosity-reducing amount of the viscosity-reducing excipient compound to a carrier solution for the protein-related process, wherein the carrier solution contains a protein of interest, and carrier solutions comprising a liquid medium in which is dissolved a protein of interest, and a viscosity-reducing excipient, wherein the viscosity of the carrier solution has a lower viscosity that that of a control solution that is substantially similar to the carrier solution except for the presence of the viscosity-reducing excipient.

Some embodiments provide methods and systems for creating ladder/standards as quality control tools for length-based separation of carbon nanotubes; determining the length purity; or measuring distribution of lengths of a collection of carbon nanotubes. Some embodiments further provide methods and systems for dispersing carbon nanotubes by conjugation of the carbon nanotubes with biomolecule moieties, specifically proteins. Further, some embodiments provide an indicator for length-based separation of carbon nanotubes via conjugation of one or more biomolecules onto the surfaces of the nanotubes. In some embodiments, such a method can include conjugating a biomolecule to the carbon nanotubes and subjecting the conjugated carbon nanotubes to silver-stained gel electrophoresis to separate the conjugated carbon nanotubes based on their lengths.